Ligand id: 7341

Name: ataluren

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 76.22
Molecular weight 284.06
XLogP 4.49
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
This drug was granted orphan designation by the European Medicines Agency (EMA) in 2005, and full apporval in 2014 for the treatment of Duchenne muscular dystrophy (DMD). Many clinical trials have been further assessing the efficacy of this drug in patients with nonsense mutation dystrophinopathies. Results from clinical trials testing ataluren have been reported [2] and more trials are underway. Click here to view current clinical trials of ataluren/PTC124 registered at Trial NCT02090959 is a confirmatory Phase III extension study in 220 patients with nonsense mutation dystrophinopathy which is a 96 week trial due for completion in mid-June 2014.
Ataluren is also being investigated for use in patients with nonsense mutation cystic fibrosis in Phase III studies (NCT00803205 and NCT01140451). A Phase IIa study in patients with nonsense mutation hemophilia A and B (NCT00947193) has been suspended.

A note of caution: The US FDA has rejected applications for approval of ataluren as it has repeatedly failed to show statistically significant results, failing both a Phase IIb study for DMD as well as a Phase III study for cystic fibrosis. The number of failures in late stage trials suggests that the only conclusion to be made is that ataluren is not clinically effective, despite being based on a sound biological mechanism. Read the In The Pipeline blogpost 'Bad News-But Not the Unexpected Kind' for further comments and debate around ataluren's future.
Mechanism Of Action and Pharmacodynamic Effects
Studies have shown that the mechanism of action involves suppression of ribosome-induced termination of protein translation at premature termination codons (PTCs) whilst still recognising genuine stop codons [4]. By increasing the ability of the ribosome to ignore PTCs, increased amounts of functional full-length proteins are produced. However, the validity of the claimed action of this chemical has been questioned [3].
In Duchenne muscular dystrophy (DMD) the dystrophin gene carries a PTC in around 10 to 15% of patients.